Business
Business & Industry News Channel
Sanofi and Lead Pharma to develop treatments for autoimmune diseases
Sanofi announced today that it has entered into a research collaboration and license agreement with Dutch biotech Lead Pharma to discover, develop and commercialize small-molecule therapies directed against the nuclear hormone receptors called ROR gamma t to treat a broad range of autoimmune disorders, including rheumatoid arthritis, psoriasis and inflammatory bowel disease, which are among the most common. Under the terms of the agreement, Sanofi and Lead Pharma will collaborate during the early phase of research and development with a goal of identifying drug candidates and beginning human trials within 3-4 years. Novo Nordisk and Karolinska Institutet join forces in the field of diabetes
Karolinska Institutet and Novo Nordisk today signed a collaboration agreement in the field of diabetes. The programme will be fully funded by Novo Nordisk. In the new international post-doctoral fellowship programme, a total of 12 post-doctoral researchers will be offered a three-year grant to support their research primarily within the field of diabetes and metabolism. The research will be performed at Karolinska Institutet in Stockholm, Sweden, but there will also be possibility for research exchange performed at Novo Nordisk Research and Development in Denmark. Duaklir® Genuair® approved in the European Union for chronic obstructive pulmonary disease
AstraZeneca today announced that Duaklir® Genuair® (aclidinium bromide/formoterol fumarate 340/12 mcg) has been granted Marketing Authorisation by the European Commission (EC) to be used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Approximately 300 million people(1) around the world live with COPD, a progressive and chronic disease where people find breathing difficult due to limited airflow. Improving the lung function and managing daily symptoms such as breathlessness are important to the management of COPD. Merck lends support in the fight against Ebola
Merck, a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors, will be donating € 250,000 to support the German Red Cross, a member of the International Federation of Red Cross and Red Crescent Societies, in the fight against Ebola. With this donation, the company is underlining social responsibility as part of its entrepreneurial approach. Novartis presents oncology research advances with new data on Zykadia(TM), Afinitor® and key pipeline compounds at ESMO 2014
Novartis will showcase new data at the European Society for Medical Oncology (ESMO) Congress, September 26-30, 2014 in Madrid, Spain. In keeping with the meeting's focus on "Precision Medicine in Cancer Care," Novartis will feature compounds that target specific pathways and molecular markers involved in cancer. The Novartis data include new analyses from the pivotal trial evaluating Zykadia(TM) (ceritinib) in ALK+ non-small cell lung cancer (NSCLC), overall survival results from the pivotal trial of the mTOR inhibitor Afinitor® (everolimus) in advanced pancreatic neuroendocrine tumors (pNET), and updated patient management data for Afinitor in advanced breast cancer. UCB expands access to clinical study data
UCB announces that it has joined the Multi-Sponsor Environment which allows for the responsible sharing of clinical study data as a way to uncover new scientific knowledge or insights, advance medicine and ultimately benefit patients and other stakeholders. In line with its vision for patient-centered leadership, UCB is the first midcap biopharma company to join this new environment. The environment allows researchers to request access to anonymised patient level data and supporting documents from clinical studies to conduct further research. Research proposals are reviewed by an Independent Review Panel.